Matthew PhD is a neuroscientist with expertise in abuse liability and pharmacology, focused on developing novel therapeutics and harm reduction tools for addiction, depression, and anxiety. He brings wide-ranging research experience across academia and industry, spanning molecular to behavioral science and preclinical to clinical development.
During his most recent work at the U.S. Food and Drug Administration, Matthew regulated and studied addictive drugs, further deepening his understanding of the scientific and regulatory considerations shaping therapeutic development. This diverse background has provided him with unique and comprehensive insights across the entire therapeutics development pipeline, from initial target identification to clinical evaluation and eventual regulatory submission.
